← Back to Search

Kinesia 360 Users for Parkinson's Disease

N/A
Waitlist Available
Led By Dustin Heldman, PhD
Research Sponsored by Great Lakes NeuroTechnologies Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group

Summary

Kinesia 360 is an ambulatory symptom monitoring device for Parkinson's Disease (PD). The aim of this study is to investigate the impact, validation, and usability of the Kinesia 360 system.

Eligible Conditions
  • Parkinson's Disease

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Kinesia 360 UsersExperimental Treatment1 Intervention
Parkinson's patients will be monitored continuously using wearable Kinesia 360 sensors.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Kinesia 360
2016
N/A
~50

Find a Location

Who is running the clinical trial?

University of RochesterOTHER
867 Previous Clinical Trials
548,837 Total Patients Enrolled
Johns Hopkins UniversityOTHER
2,326 Previous Clinical Trials
14,874,914 Total Patients Enrolled
National Institute on Aging (NIA)NIH
1,788 Previous Clinical Trials
28,184,727 Total Patients Enrolled
~5 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top